By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Antimigraine agents > Almotriptan > Almotriptan Dosage
Antimigraine agents
https://themeditary.com/dosage-information/almotriptan-dosage-7502.html

Almotriptan Dosage

Drug Detail:Almotriptan (Almotriptan [ al-moe-trip-tan ])

Drug Class: Antimigraine agents

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Migraine

Initial dose: 6.25 mg or 12.5 mg orally as a single dose
Repeat dose: If headache is relieved, but returns, may repeat with 1 dose orally provided there is a minimum interval of 2 hours between doses.
Maximum daily dose: 25 mg

Comments:

  • The safety of treating an average of more than 4 migraines per month has not been established.
  • The 12.5 mg dose tends to be more effective in adults, however as individuals may vary in their response, the dose should be individualized.
  • The effectiveness of a second dose has not been established in clinical trials.

Use: For the acute treatment of migraine attacks in patients with a history of migraine with or without aura.

Usual Pediatric Dose for Migraine

Adolescents (12 to 17 years):
Initial dose: 6.25 mg or 12.5 mg orally as a single dose
Repeat dose: If headache is relieved, but returns, may repeat 1 dose orally provided there is a minimum interval of 2 hours between doses.
Maximum daily dose: 25 mg

Comments:

  • The safety of treating an average of more than 4 migraines per month has not been established.
  • Individuals may vary in their response, the dose should be individualized.
  • The efficacy in adolescents on migraine-associated symptoms (nausea, photophobia, and phonophobia) and the effectiveness of a second dose have not been established in clinical trials.

Use: For the acute treatment of migraine headache pain in patients with a history of migraine attacks with or without aura usually lasting 4 hours or more when untreated.

Renal Dose Adjustments

  • Severe renal impairment:
Initial dose: 6.25 mg orally as a single dose
Repeat dose: If headache is relieved, but returns, may repeat 1 dose provided there is a minimum interval of 2 hours between doses.
Maximum daily dose: 12.5 mg
  • Mild or moderate renal impairment: No adjustment recommended

Liver Dose Adjustments

Initial dose: 6.25 mg orally as a single dose
Repeat dose: If headache is relieved, but returns, may repeat 1 dose provided there is a minimum interval of 2 hours between doses.
Maximum daily dose: 12.5 mg

Dose Adjustments

Elderly: Dose selection should be cautious generally starting at the lower dose.

Precautions

Safety and efficacy have not been established in patients younger than 12 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available.

Other Comments

Administration advice:

  • May take with or without food
  • If the headache is relieved after the initial dose, but returns, a second dose may be taken no sooner than 2 hours later; do not take more than 2 doses in 24 hours

General:
  • This drug should only be used where a clear diagnosis of migraine has been established; if a patient does not respond, the diagnosis of migraine should be reconsidered before treating subsequent attacks.
  • This drug is not intended to treat cluster headaches, hemiplegic, or basilar migraines or for the prophylactic treatment of migraines.
  • For patients with coronary artery disease (CAD) risk factors, a cardiovascular evaluation should be performed prior to initiating therapy.
  • Medication overuse headaches may present as migraine-like headaches or as a marked increase in migraine frequency; for patients using acute migraine medications 10 or more days per month consider withdrawal of the overused drugs and treatment of withdrawal symptoms.

Monitoring:
  • ECG monitoring should be considered in the interval following the first dose in patients with risk factors for coronary artery disease (CAD) who have satisfactorily completed a cardiovascular evaluation, in those who acquire risk factors for CAD, and in patients who experience signs or symptoms suggestive of angina following dosing.
  • Monitor for serotonin syndrome if concomitant use of selective serotonin reuptake inhibitors (SSRIs) or selective norepinephrine reuptake inhibitors (SNRIs) is necessary, particularly when starting therapy and with any increase in dose.

Patient advice:
  • Patients should be advised to talk with their doctor or pharmacist before taking any new medications or supplements.
  • Patients should be aware of the risk of serious cardiovascular side effects and the importance of seeking medical advice if they occur.
  • Patients should be informed of the possibility of developing medication overuse headaches.
  • This drug may impair judgment, thinking, or motor skills; have patient avoid driving or operating machinery until adverse effects are determined.
  • Advise patient to speak to physician or health care professional if pregnant, intend to become pregnant, or are breastfeeding.
Share this Article
Latest News
Medical News

Seed oils: Omega-6 fatty acids may lower diabetes, heart disease risk

Jun 01, 2025
Type 2 diabetes: Sugary drinks may significantly raise risk
COVID-19: Who do the new vaccine guideline changes affect?
Vitamin D supplements may help slow down aging by 3 years
Aging: Exercise timing, consistency can affect heart and lung fitness
Heart health: Exercise not enough to offset effects of poor sleep
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by